Russell Investments Group Ltd. Has $10.03 Million Stock Position in Iradimed Corporation (NASDAQ:IRMD)

Russell Investments Group Ltd. lifted its holdings in Iradimed Corporation (NASDAQ:IRMD) by 2.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 211,288 shares of the medical equipment provider’s stock after acquiring an additional 4,715 shares during the period. Russell Investments Group Ltd.’s holdings in Iradimed were worth $10,030,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp increased its holdings in shares of Iradimed by 2.6% during the third quarter. Bank of New York Mellon Corp now owns 55,540 shares of the medical equipment provider’s stock worth $2,464,000 after purchasing an additional 1,389 shares during the period. Strs Ohio increased its stake in Iradimed by 8.5% during the 3rd quarter. Strs Ohio now owns 12,800 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 1,000 shares during the period. Rice Hall James & Associates LLC raised its holdings in Iradimed by 20.1% in the 3rd quarter. Rice Hall James & Associates LLC now owns 77,506 shares of the medical equipment provider’s stock valued at $3,439,000 after acquiring an additional 12,960 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Iradimed by 0.5% during the 3rd quarter. Los Angeles Capital Management LLC now owns 53,301 shares of the medical equipment provider’s stock valued at $2,365,000 after acquiring an additional 279 shares during the period. Finally, Barclays PLC grew its holdings in shares of Iradimed by 43.0% during the 3rd quarter. Barclays PLC now owns 10,656 shares of the medical equipment provider’s stock worth $472,000 after purchasing an additional 3,203 shares in the last quarter. 92.34% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IRMD. Roth Mkm reaffirmed a “buy” rating and issued a $65.00 price target on shares of Iradimed in a research note on Monday, April 22nd. Singular Research restated a “buy” rating on shares of Iradimed in a research report on Monday, April 1st. Finally, Roth Capital reiterated a “buy” rating on shares of Iradimed in a research report on Monday, April 22nd.

Iradimed Trading Up 1.9 %

Shares of NASDAQ IRMD opened at $44.70 on Monday. The company has a market cap of $565.90 million, a price-to-earnings ratio of 31.70 and a beta of 0.86. Iradimed Corporation has a 12 month low of $36.12 and a 12 month high of $51.04. The stock has a 50-day moving average price of $42.62 and a two-hundred day moving average price of $43.20.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.01). Iradimed had a return on equity of 25.01% and a net margin of 26.48%. The company had revenue of $17.45 million for the quarter. On average, sell-side analysts predict that Iradimed Corporation will post 1.39 earnings per share for the current year.

Iradimed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Monday, May 20th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, May 17th. This represents a $0.60 dividend on an annualized basis and a yield of 1.34%. Iradimed’s dividend payout ratio is currently 42.55%.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.